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cost-effectiveness ratio (ICER). Other costs included in the model were obtained by 
the declared public budget of those Hospitals. RESULTS: The annual total therapy 
cost for etanercept, adalimumab and inﬂiximab per patient was $141,050, $158,938 
and $163,152 Mexican pesos, respectively. The ACR 70 rates responses of etanercept, 
adalimumab and inﬂiximab, indicated in clinical trials are 43%, 21% and 10% 
respectively. The ICER per additional patient achieving ACR 70 response of etanercept 
when compared with adalimumab was $81,309, and $66,976 when compared with 
inﬂiximab etanercept was a dominant alternative compared with adalimumab and 
inﬂiximab. CONCLUSIONS: According to published results, the use of etanercept in 
patients with RA is the most cost-saving alternative. If the use of etanercept is 
increased, more patients could have access to biologic therapy and the health care 
institutions in Mexico could contain costs in the treatment of RA.
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OBJECTIVES: Persistence with osteoporosis medications is a signiﬁcant clinical issue, 
with many patients discontinuing therapy after just one year. The purpose of this study 
was to estimate the lifetime clinical and economic impact of poor persistence among 
patients with osteoporosis in Brazil. METHODS: We used modeling techniques and 
data from secondary sources to quantify the impact on risks, costs, and consequences 
of hip fracture resulting from poor persistence with osteoporosis medications. All 
patients entering the model were assumed to be 65-year-old postmenopausal women, 
recently diagnosed with osteoporosis, and newly initiated on bisphosphonate therapy. 
The model calculates the risk of hip fracture as well as fracture-attributable life-years 
lost and health care costs (acute and follow-up). To estimate the impact of poor treat-
ment persistence on these measures, we contrasted model results for a scenario assum-
ing perfect compliance with therapy over each patient’s remaining years of life to 
another assuming all patients would discontinue therapy after one year. Analyses were 
performed for all patients and for a subgroup with more severe disease (t-score 2.5). 
All costs were expressed in 2006 Brazilian Reais (R$) and discounted at 5% per 
annum. RESULTS: We estimate that Brazilian patients who discontinue osteoporosis 
therapy after one year would experience 27.0 additional fractures per 100 patients, 
lose an average of nearly one year of life (0.968 fracture-attributable life years), and 
incur an average of R$3611 in additional costs of fracture-related care compared with 
perfectly compliant patients. Corresponding numbers for the subgroup of patients 
with severe osteoporosis are 35.5 additional fractures (per 100), 1.31 fracture-
 attributable life-years lost, and R$5,603 in fracture-related health care costs. 
 CONCLUSIONS: The lifetime clinical and economic consequences of poor persistence 
among osteoporosis patients in Brazil may be considerable. Programs to improve 
persistence with osteoporosis medications have the potential to beneﬁt patients and 
payers alike.
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OBJECTIVES: Traumatic fractures of the lower extremities often require prolonged 
rehabilitation or multiple procedures to achieve maximum functional recovery and, 
therefore, they are an area of substantial socioeconomic cost. Tibia fractures are the 
most common long bone fracture. Although only a relatively small percentage of the 
total of fractures—between 2% and 7%—are nonunion fractures, most of them (62%) 
affect the tibia. The aim of this analysis is to asses the cost-effectiveness of collagen-
polyvinylpyrrolidone versus surgical treatment with intra-medullar nailing in the man-
agement of nonunion tibial fractures, from the health care payer’s perspective. 
METHODS: A cost-effectiveness analysis was developed using a decision-tree model 
that simulates costs and effectiveness for a 12-month period. The effectiveness measure 
was the percentage of patients who shows radiographic fracture union at the end of 
the period of analysis. The comparators were collagen-polyvinylpyrrolidone versus 
surgical treatment with intramedullary nailing. Resource use and cost data were 
obtained from hospital records of patients being treated at a third-level hospital within 
the Mexican Social Security Institute (IMSS) and price lists and rates published by 
health institutions. Effectiveness data were obtained from international published 
 literature. Sensitivity analyses were performed to determine the results robustness. 
RESULTS: The expected costs of treatment for the alternatives were: US$2,467.3 for 
collagen-polyvinylpyrrolidone versus USD$7,920.6. Tibial fracture consolidation was 
present in 95.7% of the patients treated with intramedullary nailing and in 99.6% of 
the patients treated with collagen-polyvinylpyrrolidone. Incremental analysis shows 
collagen-polyvinylpyrrolidone as dominant alternative. CONCLUSIONS: Collagen-
polyvinylpyrrolidone is more effective and less expensive than intramedullary nailing 
for the management of patients with stable nonunion tibial fractures.
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OBJECTIVES: Knee osteoarthrosis is a multifactorial, progressive and incurable rheu-
matic ailment; most treatments look for a maximum recovery of mobility and func-
tionality of the knee joint, with a minimum risk possibility. Due to its high cost and 
invasive character, gonarthrosis surgical treatment is reserved, according to the clinical 
practice guidance available in Mexico, for severe pain and joint functionality limita-
tion cases; deﬁned as knee osteoarthrosis present in IV degree, or functional class III 
onwards. This study evaluates cost and effectiveness of the use of Hylan G-F 20 vs. 
intraarticular steroids to withhold surgery in patients with severe knee osteoarthrosis. 
METHODS: Cost-effectiveness analysis using a decision tree to simulate a hypotheti-
cal cohort behavior of patients with severe knee osteoarthrosis for a period of two 
years, from the perspective of the health service supplier. Costs were estimated using 
prices of 2008 and are expressed in US dollars (exchange rate of 11.14 pesos/1 US 
dollar). RESULTS: With Hylan G-F 20, 94.6 % of patients did not require surgery 
during the analysis period vs. 50%, in the case of those under intraarticular steroid 
treatment. Expected treatment costs: Hylan G-F 20, $2081.0, and intraarticular ste-
roids, $4593.2. The average cost-effectiveness of treatments: Hylan G-F 20, $2200.5 
and intraarticular steroids, $9111.6. Incremental analysis shows Hylan G-F 20 as 
dominant alternative. Different sensitivity analyses corroborate the dominance rela-
tionship exercised by Hylan G-F 20 over the steroid treatment. CONCLUSIONS: 
Hylan G-F 20 is a more effective and less expensive alternative than steroid treatment 
to withhold surgery in patients with severe knee osteoarthrosis.
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ZOLEDRÓNICO, RISEDRONATO, ALENDRONATO E IBANDRONATO EN 
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OBJETIVO: Análisis costo-efectividad de los tratamientos, Ácido Zoledrónico, Rise-
dronato, Alendronato e Ibandronato, en el manejo de la osteoporosis en posmenopáu-
sicas. Impacto de la adherencia a los tratamientos anuales y semanales para la 
osteoporosis, en términos de: número de fracturas de cadera, costos asociados a las 
fracturas de cadera y días de hospitalización. MÉTODOS: Retrospectivo, analítico. 
Información de efectividad a partir de ensayos clínicos, lo que representa un Nivel de 
evidencia I, grado de recomendación A. Los costos de medicamentos a precio de 
mercado y los costos hospitalarios a partir de una muestra representativa de centros 
de salud de complejidad mediana y alta en Venezuela. RESULTADOS: La relación 
costo-efectividad (costo-por incremento de 1% de la densidad mineral ósea) fue en el 
caso de cadera, para Acido Zoledrónico US$ 13,178, Alendronato US$ 15,521 e 
Ibandronato US$ 20,625. El costo de una fractura de cadera se estimó en US$ 34.884 
(hospitalización, cirugía, cuidados, prótesis, andadera, exámenes). De acuerdo a la 
población femenina venezolana, la prevalencia de padecer osteoporosis, los riesgos de 
fractura asociados a la adherencia a los tramientos y los costos, se estimó que el costo 
social de las fracturas de cadera estaría para el tratamiento semanal en US$ 1.015.984, 
para el anual en US$ 1.015–984 y sin tratamiento US$ 1.344.403. Los días de hospi-
talización se estimaron en: tratamiento semanal 116.500 días, anual 85.800 días y sin 
tratamiento en 154.158 días. CONCLUSIONES: Los tratamientos anuales para 
el manejo de la osteoporosis, debido a sus costos, efectividad y mayores niveles de 
adherencia representan una opción eﬁciente en el manejo de la osteoporosis. La mayor 
adherencia a los tratamientos permite reducir el número de fracturas y consumo de 
recursos sanitarios, permitiendo una contención de costos y una minimización de los 
costos de oportunidad al posibilitar un uso más eﬁciente de los recursos.
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OBJECTIVES: To analyse the cost-minimization of viscosupplmentation in compari-
son with arthroscopy/lavage for the treatment of moderate osteoarthritis of knee. 
METHODS: A cost-minimization analysis from the Brazilian Private Payer perspec-
tive, with a time horizon of 2 years was conduct. A decision tree considering the 
probabilities of treatment fail or success, were performed. Study comparators exam-
ined were Hyaluronic Acid (Synvisc©) and Arthroscopy with Lavage (Arthroscopy). 
The clinical aspects regarding beneﬁts and probabilities data were extracted from 
clinical trials and meta-analysis of clinical trials for the alternatives. The analysis was 
based on Brazilian current clinical practice. Treatment costs were collected from a 
private payer’s database. Costs and beneﬁts were validated by a panel of Brazilian 
specialists from payers. Due to short term analysis discounting was not applied, the 
results were converted in US Dollars (R$2.3/USD 1.00). A one-way sensitivity analysis 
was performed. RESULTS: Patients using Hyaluronic Acid get the lowest total cost 
per treatment (Synvisc©  USD 2,042 OR R$4.697; Arthroscopy  USD 2136 OR 
R$4.913). The results were sensitive to Hyaluronic Acid cost regarding all other 
